Q-omics provides the consensus-scored NAA16 profile across patient tissues and cancer cell-line models. NAA16 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, NAA16 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, NAA16 RNA expression shows 21,069 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, COAD, and ACC as cancer lineages where NAA16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAA16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAA16 survival associations across molecular data types. NAA16 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAA16 RNA expression–survival associations across cancer types. High NAA16 expression shows unfavorable associations in KICH, ACC, UVM and CESC, but favorable associations in MESO and UCEC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KICH as the clearest survival context for NAA16 RNA expression.
This table summarizes NAA16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NAA16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAA16 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, LIHC, CHOL and READ. The COAD box plot shows higher NAA16 RNA expression in tumor versus normal tissue (log2 FC = +0.946, t-test p < 0.001).
This table shows molecular features associated with NAA16 in patient tissues and cancer cell lines. In patient samples, NAA16 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NAA16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
